---
document_datetime: 2025-12-29 10:34:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tidhesco.html
document_name: tidhesco.html
version: success
processing_time: 0.0462828
conversion_datetime: 2025-12-31 04:17:51.831596
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tidhesco

[RSS](/en/individual-human-medicine.xml/67667)

##### Application withdrawn

The application for this medicine has been withdrawn

ivosidenib Medicine Human Application withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [News on Tidhesco](#news-on)
- [More information on Tidhesco](#more-information-on-tidhesco-62360)
- [More information on Tidhesco](#related-medicines)

- Application under evaluation
- Withdrawal of application

## Overview

The applicant withdrew the marketing authorisation application for Tidhesco (ivosidenib) on 27 March 2023. It was a duplicate of the application for another medicine, Tibsovo, which is now authorised for use in the European Union.

The application for Tidhesco was withdrawn after EMA's human medicines committee, CHMP, had adopted a positive opinion recommending the granting of a marketing authorisation. At the time of withdrawal, the European Commission had not yet granted marketing authorisation for this product. Further details are included in the withdrawal letter.

## Key facts

Name of medicine Tidhesco Active substance Ivosidenib International non-proprietary name (INN) or common name ivosidenib Therapeutic area (MeSH) Leukemia, Myeloid, Acute Anatomical therapeutic chemical (ATC) code L01XX62 EMA product number EMEA/H/C/006174

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation applicant Les Laboratoires Servier Withdrawal of application 27/03/2023

## All documents

Withdrawal assessment report for Tidhesco

Adopted

Reference Number: EMA/173663/2023

English (EN) (5.06 MB - PDF)

**First published:** 30/05/2023

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-tidhesco_en.pdf)

Withdrawal letter : Tidhesco

English (EN) (45.39 KB - PDF)

**First published:** 21/06/2023

[View](/en/documents/withdrawal-letter/withdrawal-letter-tidhesco_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### News on Tidhesco

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023) 24/02/2023

#### More information on Tidhesco

CHMP summary of positive opinion for Tidhesco

Adopted

Reference Number: EMA/180261/2023 Rev.1

English (EN) (161.32 KB - PDF)

**First published:** 24/02/2023

**Last updated:** 26/04/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tidhesco_en.pdf)

#### More information on Tidhesco

- [EU/3/16/1802 - orphan designation for treatment of acute myeloid leukaemia](/en/medicines/human/orphan-designations/eu-3-16-1802)

**This page was last updated on** 21/06/2023

## Share this page

[Back to top](#main-content)